These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 31097390)
1. A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder. Kao C; McNamara M; Alley C; Spector N; Jauhari S; Gupta RT; Zhang T; Zhu J Clin Genitourin Cancer; 2019 Jun; 17(3):e672-e677. PubMed ID: 31097390 [No Abstract] [Full Text] [Related]
2. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation. Morsch R; Rose M; Maurer A; Cassataro MA; Braunschweig T; Knüchel R; Vögeli TA; Ecke T; Eckstein M; Weyerer V; Esposito I; Ackermann M; Niegisch G; Gaisa NT; BMC Cancer; 2020 Mar; 20(1):230. PubMed ID: 32188412 [TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab for the treatment of bladder cancer. Sundahl N; Rottey S; De Maeseneer D; Ost P Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318 [TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population. Chen WC; Chu PY; Lee YT; Lu WB; Liu CY; Chang PM; Yang MH Medicine (Baltimore); 2017 Dec; 96(52):e9519. PubMed ID: 29384959 [TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer. Sheth S; Weiss J Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975 [TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Hahn AW; Chahoud J; Campbell MT; Karp DD; Wang J; Stephen B; Tu SM; Pettaway CA; Naing A Invest New Drugs; 2021 Oct; 39(5):1405-1410. PubMed ID: 33770291 [TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab Treatment and Pathologic Therapeutic Evaluation for Granulocyte Colony-stimulating Factor-producing Bladder Cancer: A Case Report and Literature Review. Muramatsu-Maekawa Y; Taniguchi T; Ito H; Nakane K; Kato T; Tsuchiya T; Miyazaki T; Koie T; Mizutani K J Immunother; 2020 May; 43(4):134-138. PubMed ID: 32080020 [TBL] [Abstract][Full Text] [Related]
8. Squamous differentiation is a potential biomarker predicting tumor progression in patients treated with pembrolizumab for urothelial carcinoma. Miyama Y; Morikawa T; Miyakawa J; Koyama Y; Kawai T; Kume H; Ushiku T Pathol Res Pract; 2021 Mar; 219():153364. PubMed ID: 33610951 [TBL] [Abstract][Full Text] [Related]
10. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946 [TBL] [Abstract][Full Text] [Related]
11. Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature. Wilde L; Ali SM; Solomides CC; Ross JS; Trabulsi E; Hoffman-Censits J Clin Genitourin Cancer; 2017 Jun; 15(3):e521-e524. PubMed ID: 28143711 [No Abstract] [Full Text] [Related]
12. Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report. Song HN; Kang MG; Park JR; Hwang JY; Kang JH; Lee WS; Lee GW Cancer Res Treat; 2018 Oct; 50(4):1458-1461. PubMed ID: 29361819 [TBL] [Abstract][Full Text] [Related]
13. A network meta-analysis of the PD(L)-1 inhibitors in the salvage treatment of urothelial bladder cancer. Rassy EE; Bakouny Z; Aoun F; Haddad FG; Sleilaty G; Assi T; Kattan J Immunotherapy; 2018 Jun; 10(8):657-663. PubMed ID: 29562804 [TBL] [Abstract][Full Text] [Related]
14. Three more immune checkpoint inhibitors for advanced bladder cancer. Med Lett Drugs Ther; 2017 Dec; 59(1535):e202-e203. PubMed ID: 29186087 [No Abstract] [Full Text] [Related]
15. Advanced Bladder Cancer Rechallenged With an Immune Checkpoint Inhibitor: A Case Report. Bat T; Buck DA; Nathan R; Cinquino J; Sikorski M; Elefante A; Herbst L; Sule N; Fabiano A; George S Urology; 2019 Sep; 131():24-26. PubMed ID: 31059726 [No Abstract] [Full Text] [Related]
16. Focal immune-related pancreatitis occurring after treatment with programmed cell death 1 inhibitors: a distinct form of autoimmune pancreatitis? Capurso G; Archibugi L; Tessieri L; Petrone MC; Laghi A; Arcidiacono PG Eur J Cancer; 2018 May; 95():123-126. PubMed ID: 29530539 [No Abstract] [Full Text] [Related]
17. Pembrolizumab in the treatment of advanced urothelial cancer. Lundgren KT; Farina MS; Bellmunt J Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016 [TBL] [Abstract][Full Text] [Related]
18. NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good? Gupta S; Kamat AM Nat Rev Urol; 2020 Sep; 17(9):491-492. PubMed ID: 32632305 [TBL] [Abstract][Full Text] [Related]
19. Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab. Owosho AA; Randazzo J; Rosen EB; Estilo CL; Huryn JM; Chi P; Yom SK Oral Oncol; 2016 Dec; 63():e1-e3. PubMed ID: 27743938 [No Abstract] [Full Text] [Related]
20. CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma. Migden MR; Chandra S; Rabinowits G; Chen CI; Desai J; Seluzhytsky A; Sasane M; Campanelli B; Chen Z; Freeman ML; Ibrahim SF; Khushalani NI; Andria M; Ruiz E Future Oncol; 2020 Feb; 16(4):11-19. PubMed ID: 31951149 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]